MYRIAD GENETICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M |
| Cost of revenue | $247.9M | $252.2M | $236.2M | $202.0M | — |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M | — |
| Selling, general & administrative | — | — | $572.9M | $514.7M | $537.8M |
| Research and development | $106.8M | $113.4M | $88.7M | $85.4M | $81.9M |
| Operating expenses | $963.8M | $708.9M | $774.4M | $617.0M | — |
| Operating income | -$387.2M | -$123.5M | -$257.4M | -$140.6M | -$190.5M |
| Interest expense | $10.5M | $2.8M | $2.9M | $3.2M | $6.6M |
| Pretax income | -$395.1M | -$123.5M | -$262.2M | -$140.6M | -$57.1M |
| Income tax expense | -$29.2M | $3.8M | $1.1M | -$28.6M | -$29.9M |
| Net income | -$365.9M | -$127.3M | -$263.3M | -$112.0M | -$27.2M |
| Balance Sheet | |||||
| Cash and equivalents | $149.6M | $102.4M | $132.1M | $56.9M | $257.4M |
| Current assets | $332.6M | $298.0M | $313.6M | $274.6M | $484.8M |
| Total assets | $706.6M | $1.0B | $1.1B | $1.2B | $1.3B |
| Current liabilities | $133.8M | $164.1M | $155.9M | $137.2M | $204.3M |
| Total liabilities | $338.6M | $326.5M | $363.3M | $312.9M | $352.9M |
| Total debt | $125.0M | $40.5M | — | — | — |
| Stockholders' equity | $368.0M | $701.1M | $783.2M | $885.8M | $967.8M |
| Cash Flow Statement | |||||
| Cash from operations | $1.8M | -$8.7M | -$110.9M | -$106.3M | $18.6M |
| Depreciation and amortization | $19.5M | $19.5M | $19.1M | $11.6M | $12.1M |
| Stock-based compensation | $35.2M | $49.8M | $40.7M | $38.1M | $36.3M |
| Capital expenditure | — | — | — | $45.3M | $18.0M |
| Free cash flow | — | — | — | -$151.6M | $600,000 |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $319.4M | $56.6M | $0 | $16.9M | $0 |
Shares outstanding 94.4M · Free float 98.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.